Profile
Sector:
HealthcareCountry:
United StatesIPO:
11 February 2011Website:
http://talphera.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 22:18:23 GMTDividend
Analysts recommendations
Institutional Ownership
TLPH Latest News
SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors.
The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured over the first 24 hours, with patients completing the study after 72 hours Dr. Stuart Goldstein, a world-renowned nephrologist, is the first physician to enroll a patient in the NEPHRO CRRT study SAN MATEO, Calif. , Aug. 19, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the first patient has been enrolled in the NEPHRO CRRT study.
SAN MATEO, Calif. , Aug. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2024 financial results after market close on Wednesday, August 14, 2024, then host a live webcast and conference call at 4:30 p.m.
SAN MATEO, Calif. , May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company specializing in developing and selling innovative therapies for medically supervised use, announced today that its management will take part in a fireside chat at the A.G.P.
What type of business is Talphera?
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
What sector is Talphera in?
Talphera is in the Healthcare sector
What industry is Talphera in?
Talphera is in the Drug Manufacturers - Specialty & Generic industry
What country is Talphera from?
Talphera is headquartered in United States
When did Talphera go public?
Talphera initial public offering (IPO) was on 11 February 2011
What is Talphera website?
https://talphera.com
Is Talphera in the S&P 500?
No, Talphera is not included in the S&P 500 index
Is Talphera in the NASDAQ 100?
No, Talphera is not included in the NASDAQ 100 index
Is Talphera in the Dow Jones?
No, Talphera is not included in the Dow Jones index
When was Talphera the previous earnings report?
No data
When does Talphera earnings report?
The next expected earnings date for Talphera is 08 November 2024